Catalyst Biosciences

Catalyst Biosciences company information, Employees & Contact Information

Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.

Company Details

Employees
12
Address
611 Gateway Blvd, South San Francisco,ca 94080,united States
Phone
+1 650 871 0761
Email
in****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, CA
Looking for a particular Catalyst Biosciences employee's phone or email?

Catalyst Biosciences Questions

News

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 - GlobeNewswire

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 GlobeNewswire

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors - GlobeNewswire

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors GlobeNewswire

Catalyst Biosciences Completes First Steps in Reverse Merger Plan - Yahoo Finance

Catalyst Biosciences Completes First Steps in Reverse Merger Plan Yahoo Finance

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - GlobeNewswire

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock GlobeNewswire

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - GlobeNewswire

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China GlobeNewswire

Catalyst Biosciences Announces Completion of Business - GlobeNewswire

Catalyst Biosciences Announces Completion of Business GlobeNewswire

Catalyst Biosciences Announces Global License and - GlobeNewswire

Catalyst Biosciences Announces Global License and GlobeNewswire

Top Catalyst Biosciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant